These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
688 related articles for article (PubMed ID: 20569105)
1. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105 [TBL] [Abstract][Full Text] [Related]
2. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]. Li X; Lin JF Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817 [TBL] [Abstract][Full Text] [Related]
3. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370 [TBL] [Abstract][Full Text] [Related]
4. [Exploration of the classification of polycystic ovarian syndrome]. Lin JF; Li X; Zhu MW Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924 [TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204 [TBL] [Abstract][Full Text] [Related]
6. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772 [TBL] [Abstract][Full Text] [Related]
7. Plasma selenium levels in Turkish women with polycystic ovary syndrome. Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536 [TBL] [Abstract][Full Text] [Related]
8. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907 [TBL] [Abstract][Full Text] [Related]
9. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. Li L; Chen X; He Z; Zhao X; Huang L; Yang D J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573 [TBL] [Abstract][Full Text] [Related]
10. [Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome]. Hu WH; Qiao J; Zhao SY; Zhang XW; Li MZ Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):487-91. PubMed ID: 17068620 [TBL] [Abstract][Full Text] [Related]
11. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276 [TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study. Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387 [TBL] [Abstract][Full Text] [Related]
13. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA; Shin SY; Yoon BK; Choi D Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414 [TBL] [Abstract][Full Text] [Related]
14. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615 [TBL] [Abstract][Full Text] [Related]
15. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Pigny P; Cortet-Rudelli C; Decanter C; Deroubaix D; Soudan B; Duhamel A; Dewailly D Fertil Steril; 2000 May; 73(5):972-7. PubMed ID: 10785223 [TBL] [Abstract][Full Text] [Related]
16. Adrenal androgen excess and body mass index in polycystic ovary syndrome. Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100 [TBL] [Abstract][Full Text] [Related]
17. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652 [TBL] [Abstract][Full Text] [Related]
18. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320 [TBL] [Abstract][Full Text] [Related]
19. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease]. Chen Y; Wang XJ; Jin HL; Jin L Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352 [TBL] [Abstract][Full Text] [Related]
20. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study. Singh S; Akhtar N; Ahmad J Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]